Search
Paclitaxel Treatment Options
A collection of 2051 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States . Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
1645 - 1656 of 2051
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Offer
Join Thousands Waiting for Retatrutide
Retatrutide could change the weight loss landscape. Unlike semaglutide or tirzepatide, it activates three hormone receptors simultaneously — and early data shows it:
✅ Outpaced existing GLP-1 medications for weight loss in clinical trials
✅ Improved blood sugar, blood pressure, and cholesterol beyond weight loss alone
✅ Delivered results with a simple once-weekly injection
✅ Now in Phase 3 trials with FDA submission expected in the next 1–2 years
Join the waiting list. One email when it launches — that's it.
✅ Outpaced existing GLP-1 medications for weight loss in clinical trials
✅ Improved blood sugar, blood pressure, and cholesterol beyond weight loss alone
✅ Delivered results with a simple once-weekly injection
✅ Now in Phase 3 trials with FDA submission expected in the next 1–2 years
Join the waiting list. One email when it launches — that's it.
Conditions:
Weight Loss
Featured Offer
Discover Affordable Semaglutide Providers
We Checked the Checkout Page on Every Semaglutide Provider. Here's What We Found.
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
Conditions:
Weight Loss
Morbid Obesity
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer
Completed
A treatment study is being conducted by the University of Rochester Cancer Center (URCC) in which patients with non-small cell lung cancer will be treated with radiation therapy and a drug called paclitaxel. Paclitaxel is a natural product with anticancer properties. The first purpose of this study is to determine the dose of paclitaxel which, when given in combination with radiation therapy, will provide the greatest effect have the least side effects. To determine this, patients will be put on... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2015
Locations: University of Rochester, Dept. Radiation Oncology, Rochester, New York
Conditions: Carcinoma, Non-Small-Cell Lung
TAXUS Libertē Post Approval Study
Completed
The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAPT) drug regimen.
This study will also contribute patient data to an FDA-requested and industry-sponsored research study that will evaluate the optimal duration of dual antiplatelet therapy (DAPT Stud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2015
Locations: Advanced Cardiac Specialists, Mesa, Arizona +81 locations
Conditions: Coronary Artery Disease
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying two different regimens of combination chemotherapy and comparing them to see how well they work in treating patients with high-risk primary stage II or stage III breast cancer.
Gender:
ALL
Ages:
60 years and below
Trial Updated:
07/07/2015
Locations: Banner Good Samaritan Medical Center, Phoenix, Arizona +1 locations
Conditions: Breast Cancer
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Completed
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum tolerated dose (MTD) expansion (phase II) in ovarian and bladder cancer patients
The clinical trial is now in the MTD (phase II) portion of the study enrolling bladder cancer patients. Enrollment of ovarian patients is complete.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/07/2015
Locations: Gynecologic Oncology Associates, Newport Beach, California +10 locations
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Completed
The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2015
Locations: Florida Cancer Specialists, Fort Myers, Florida +22 locations
Conditions: Carcinoma of Unknown Primary
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
Completed
To determine safety and maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects with advanced or metastatic solid tumors
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/03/2015
Locations: Usc/Norris Comprehensive Cancer Center, Los Angeles, California +4 locations
Conditions: Advanced Cancer
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
Completed
The main purpose of this research study is to evaluate whether Abraxane and gemcitabine are effective in treating patients with operable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/15/2015
Locations: TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona +3 locations
Conditions: Resectable Pancreatic Cancer
Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
Completed
This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
06/06/2015
Locations: University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico +2 locations
Conditions: Non-small Cell Lung Cancer
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining tirapazamine, carboplatin, and paclitaxel in treating patients who have advanced malignant solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2015
Locations: City of Hope Medical Center, Duarte, California +3 locations
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer
Terminated
This study seeks to establish the safety of gemcitabine, paclitaxel and low-dose radiation in recurrent, metastatic head and neck cancer through a two-stage dose escalation study, first with Gemcitabine dose escalation and then with low-dose radiation escalation.
Treatment Schedule
Treatment will be administered on an inpatient or outpatient basis.
* Gemcitabine:2000 to 3000mg/m2 IV (in the vein) on days 1 and 15 every 28 days over 30-60 minutes.
* Paclitaxel: 150 mg/m2 IV(in the vein)on days... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2015
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Head and Neck Cancer
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Completed
This phase I clinical trial studies the side effects and the best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with locally advanced or metastatic solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by blocking them from dividing. Giving... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2015
Locations: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania +2 locations
Conditions: Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Completed
This phase I trial is studying the side effects and best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with advanced solid cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with carbopl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2015
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +6 locations
Conditions: Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Hereditary Breast and Ovarian Cancer Syndrome
1645 - 1656 of 2051